Concord Biotech · NSE: CONCORDBIO · BSE: 543960
Q3 FY24 results · Oct–Dec 2023
Concord Biotech reported revenue from operations of ₹240.80 crore and net profit of ₹77.57 crore for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 240.80 | — | — | 262.35 | −8.2% |
| Other income | 8.19 | — | — | 8.13 | +0.7% |
| Total income | 248.98 | — | — | 270.47 | −7.9% |
| Profit before share of associates & JVs and tax | 100.08 | — | — | 113.18 | −11.6% |
| Share of profit/(loss) of associates & JVs | 3.02 | — | (3.47) | ||
| Net profit for the period | 77.57 | — | — | 81.02 | −4.3% |
| EPS, basic (₹) | 7.41 | — | — | 7.74 | −4.3% |
| Net margin (%) | 32.2 | — | 30.9 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 240.80 | — | — | 262.35 | −8.2% |
| Other income | 8.19 | — | — | 8.13 | +0.7% |
| Total income | 248.98 | — | — | 270.47 | −7.9% |
| Profit before tax | 100.08 | — | — | 113.18 | −11.6% |
| Net profit for the period | 74.55 | — | — | 84.49 | −11.8% |
| EPS, basic (₹) | 7.13 | — | — | 8.08 | −11.7% |
| Net margin (%) | 31.0 | — | 32.2 |
Consolidated
- Filed with BSE
- 20 Feb 2024, 17:45 IST
- Board meeting
- 08 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 20 Feb 2024, 17:45 IST
- Board meeting
- 08 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE